Treatment of alzheimer's disease: Symptomatic and disease-modifying approaches

Current Aging Science

Volumn 3, Issue 1, 2010, Pages 46-56

  Galimberti, Daniela ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Amyloid; Disease modifying drugs; Inflammation; Tau

Indexed keywords

ACC 001; ACETYLCHOLINE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AZD 103; BAPINEUZUMAB; BMS 708163; CHOLESTEROL; CHOLINESTERASE INHIBITOR; COLOSTRININ; DONEPEZIL; EHT 0202; ETAZOLATE; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; IMMUNOGLOBULIN; INDOMETACIN; INOSITOL; IRON; LY 2062430; MABT 5102A; MEMANTINE; METHYLTHIONINIUM CHLORIDE; POLYPEPTIDE; REMBER; RIVASTIGMINE; ROSIGLITAZONE; SEMAGACESTAT; TACRINE; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANEMIA; ANOREXIA; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INFECTION; INFLAMMATION; LIVER TOXICITY; MENINGOENCEPHALITIS; NAUSEA; NEPHROTOXICITY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; VACCINATION; VOMITING;

ALZHEIMER DISEASE; AMYLOID; ANTI-INFLAMMATORY AGENTS; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; HUMANS; TAU PROTEINS;

EID: 77953778864     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811003010046     Document Type: Article

References (95)

1. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2009; 3(Suppl): 470S-4S.
2. Rak M, Del Bigio MR, Mai S, Westaway D and Gough K. Dense-core and diffuse Aβ plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy. Biopolymers 2007; 87(4): 207-17.
3. Hoozemans JJM, Veerhuis R, Rozemuller JM and Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Neurosci 2006; 24: 157-65.
4. Galimberti D, Fenoglio C and Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci 2008; 1(1): 30-41.
5. Reddy VP, Zhu X, Perry G and Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16(4): 763-74.
6. Adlard PA and Bush AI. Metals and Alzheimer's disease. J Alzheimers Dis 2006; 10(2-3): 145-63.
7. Stefani M, Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimer Res 2009; 6(1): 15-29.
8. Lawrence AD and Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res 1998; 23(5): 787-94.
9. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 2002; 14(Suppl 1): 93-126.
10. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
11. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
12. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treatingdementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148(5): 379-97.
13. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from American College of Physicians and the America Academy of Family Physicians. Ann Int Med 2008; 148: 370-8.
14. Alva G and Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont) 2008; 5(11): 27-36.
15. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand ST, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. Arch Intern Med 2009; 169(9): 867-73.
16. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372(9634): 207-15.
17. Barten DM and Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008; 37: 171-86.
18. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20(4): 154-9.
19. Vassar R. BACE1: the β-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004; 23(1-2): 105-14.
20. Allinson TM, Parkin ET, Turner AJ and Hooper NM. ADAMs family members as amyloid precursor protein -secretases. J Neurosci Res 2003; 74(3): 342-52.
21. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H and Haass C. Reconstitution of -secretase activity. Nat Cell Biol 2003; 5(5): 486-8.
22. Koo EH and Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat Med 2004; 10 (Suppl): S26-33.
23. Storey E, Spurck T, Pickett-Heaps J, Beyreuther K and Masters CL. The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites. Brain Res 1996; 735(1): 59-66.
24. Yamazaki T, Koo EH and Selkoe DJ. Cell surface amyloid β-protein precursor colocalizes with β 1 integrins at substrate contact sites in neural cells. J Neurosci 1997; 17(3): 1004-10.
25. Ho A and Südhof TC. Binding of F-spondin to amyloid-β precursor protein: a candidate amyloid-β precursor protein ligand that modulates amyloid-β precursor protein cleavage. Proc Natl Acad Sci USA 2004; 101(8): 2548-53.
26. Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, et al. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995; 81(4): 525-31.
27. Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 2004; 23(20): 4106-15.
28. Leyssen M, Ayaz D, Hébert SS, Reeve S, De Strooper and Hassan BA. Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J 2005; 24(16): 2944-55.
29. Yoshikawa K, Aizawa T and Hayashi Y. Degeneration in vitro of postmitotic neurons overexpressing the Alzheimer amyloid protein precursor. Nature 1992; 359(6390): 64-7.
30. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005; 307(5713): 1282-8.
31. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-6.
32. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001; 8(Suppl 1): 28-35.
33. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28(4): 537-47.
34. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67(10): 1757-63.
35. Santa-Maria I, Hernández F, Del Rio J, Moreno FJ and Avila J. Tramiprosate, a drug of potential interest for the treatment of Alzheimers disease, promotes an abnormal aggregation of tau. Mol Neurodegener 2007; 2(1): 17.
36. Gladkevich A, Bosker F, Korf J, Yenkoyan K, Vahradyan H and Aghajanov M. Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders -- therapeutic potential or a mirage? Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(7): 1347-55.
37. Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K and Georgiades JA. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz) 1999; 47(6): 377-85.
38. Bilikiewicz A and Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimers Dis 2004; 6: 17-26.
39. McLaurin J, Golomb R, Jurewicz A, Antel JP and Fraser PE. Inositol stereoisomers stabilizes an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit A β-induced toxicity. J Biol Chem 2000; 275: 18495-502.
40. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, et al. Orally available compound prevents deficits in memory caused by the Alzheimer Amyloid-boligomers. Ann Neurol 2006; 60: 668-76.
41. Schenk D, Barbour R and Dunn W. Immunization with amyloid- attenuates Alzheimer-disease-like pathology in PDAPP mouse. Nature 1999; 400: 173-7.
42. Gilman S, Koller M and Black RS. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-62.
43. Hock C and Nitsch R. Clinical observations with AN1792 using TAPIR analyses. Neurodegenerative Dis 2005; 2: 273-6.
44. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-23.
45. Grundman M and Black R. Clinical trials of bapineuzumab, a β-amyloidtargeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers Dement 2008; 4(4 Suppl 2): T166.
46. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ 42 independently of cyclooxygenase activity. Nature 2001; 414(6860): 212-6.
47. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, et al. Selected nonsteroidal anti-inflammatory drugs and their derivatives target g-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-26.
48. Lleó A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, et al. Non steroidal anti-inflammatory drugs lower A 42 and change presenilin1 conformation. Nat Med 2004; 10: 1065-6.
49. Townsend KP and Praticò D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005; 19(12): 1592-601.
50. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007; 8: 54.
51. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and A levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007; 21(4): 292-9.
52. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, et al. Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7(6): 468-9.
53. Pollack SJ and Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of promiscuous protease. Curr Opin Investig Drugs 2005; 6: 35-47.
54. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the -secretase inhibitor LY-411,575 inhibit β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-82.
55. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 2005; 28: 126-32.
56. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66: 602-4.
57. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65(8): 1031-8.
58. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008; 106(1): 392-404.
59. Huang W, Yu H, Sheng R, Li J and Hu Y. Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors. Bioorg Med Chem 2008; 16(24): 10190-7.
60. Choi YH, Yon GH, Hong KS, Yoo DS, Choi CW, Park WK, et al. In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med 2008; 74(11): 1405-8.
61. Shimmyo Y, Kihara T, Akaike A, Niidome T and Sugimoto H. Epigallocatechin-3-gallate and curcumin suppress amyloid -induced -site APP cleaving enzyme-1 upregulation. Neuroreport 2008; 19(13): 1329-33.
62. Laras Y, Garino C, Dessolin J, Weck C, Moret V, Rolland A, et al. New N(4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors. J Enzyme Inhib Med Chem 2009; 24(1): 181-7.
63. Castellani RJ, Nunomura A, Lee H, Perry G and Smith MA. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Dis 2008; 14: 377-83.
64. Wischik CM, Edwards PC, Lai RY, Roth M and Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996; 93(20): 11213-8.
65. TM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 2008; 4(4 Suppl.2): T167.
66. Balaraman Y, Limaye AR, Levey AI and Srinivasan S. Glycogen synthase kinase 3b and Alzheimers disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 2006; 63: 1226-35.
67. Martinez A and Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 2008; 15: 181-91.
68. Schneider A and Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008; 5: 443-57.
69. McGeer PL, Schulzer M and Mc Geer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
70. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-69.
71. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
72. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-26.
73. Scharf S, Mander A, Ugoni A, Vajda F and Christophidis N. A double-blind, placebo controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
74. Soininen H, West C, Robbins J and Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23(1): 8-21.
75. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lowe Aβ 42 in vivo. J Clin Invest 2003; 112(3): 440-9.
76. Aisen PS, Marin DB, Brickman AM, Santoro J and Fusco M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheirmers Dis Assoc Disord 2001; 15(2): 96-101.
77. Aisen PS, Schmeidler J and Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002; 58(7): 1050-4.
78. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11.
79. Tabet N and Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002: CD003673.
80. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6(4): 246-54.
81. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008; 300(15):1774-83.
82. Barten DM and Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008; 37: 171-86.
83. Bush AI, Pettingell WH, Multhaup G, Paradis M, Vonsattel JP, Gusella JF, et al. Rapid induction of Alzheimer A amyloid formation by zinc. Science 1994; 265: 1464-67.
84. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 2008; 15: 223-40.
85. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits -amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30: 665-76.
86. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting A as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomized, placebo-controlled trial. Lancet Neurol 2008; 7(9): 779-86.
87. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting A amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003; 60: 1685-91.
88. Jenagaratnam L and McShane R. Clioquinol for the treatment of Alzheimer's Disease. Cochrane Database Syst Rev 2006; 25(1): CD005380.
89. Hooijmans CR and Kiliaan AJ. Fatty acids, lipid metabolism and Alzheimer pathology. Eur J Pharmacol 2008; 585: 176-96.
90. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
91. Vasdev S, Gill V and Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem Biophys 2007; 49: 48-63.
92. Jick H, Zornberg GL, Jick S and Seshadri S. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
93. Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement 2008; 4(2): 145-53.
94. Holtzman JH. Amyloid- vaccination for Alzheimer's dementia. Lancet 2008; 372: 1381.
95. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8): 734-46.